Companies › KALA
KALA BIO Inc (KALA)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001479419 · EDGAR filings · Updated 2026-07-23
KALA BIO Inc (KALA) has reported institutional ownership of 0.2%, with 27 institutional managers holding positions valued at $293.9K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).
Filings this week (2)
- 2026-07-23 — Current report (8-K) filed
- 2026-07-22 — Prospectus supplement (424B5) filed
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Latest updates
- 2026-07-02 — SCHEDULE 13D/A filed
- 2026-06-25 — EFFECT filed
- 2026-06-12 — S-3/A filed
- 2026-05-15 — SCHEDULE 13G/A filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, KALA BIO Inc has 27 institutional holders and institutional ownership of 0.2%.
Insider activity
Insiders reported 27 transactions (0 buys, 21 sells) across 13 reporting insiders, with a net reported value of −$1.55M.
Data flags from SEC filings
Related companies
Akari Therapeutics PLC ADR (AKTX) · Nuwellis Inc (NUWE) · MANGOCEUTICALS INC (MGRX) · FIBROBIOLOGICS INC (FBLG) · NEUROSENSE THERAPEUTICS LTD (NRSN) · Tenon Medical Inc (TNON)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-23.